Thursday - April 16, 2026

Category Archives: Marketing & Sales

TECHSPO San Antonio 2026 Unites Business, Tech and Marketing Leaders for High-Impact Expo

San Antonio, TX – TECHSPO San Antonio Technology Expo returns October 29-30, 2026, to The Westin San Antonio North Hotel, uniting business leaders, technologists, marketers, and innovators for a high-impact, two-day showcase of next-generation digital technology. Part of the globally recognized … Continue reading →

Becker Muscular Dystrophy Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Epirium Bio, Immuno Forge, Italfarmaco, Santhera Pharmaceuticals

Becker Muscular Dystrophy pipeline constitutes 8+ key companies continuously working towards developing 8+ Becker Muscular Dystrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.   “Becker Muscular Dystrophy Pipeline Insight, 2026“ … Continue reading →

NSCLC Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | AbbVie, AstraZeneca and Daiichi Sankyo, Shanghai Henlius Biotech, Moderna Therapeutics/ Merck, BeyondSpring, Cullinan

The Key Non-Small Cell Lung Cancer Companies in the market include 0- AbbVie, AstraZeneca and Daiichi Sankyo, Shanghai Henlius Biotech, Moderna Therapeutics/ Merck, BeyondSpring, Cullinan Oncology/ Taiho Pharma, Genentech/Roche, Betta Pharma/ Xcovery, Pfizer, Takeda Pharmaceuticals, AstraZeneca, Janssen, Boehringer Ingelheim, Pfizer, … Continue reading →

Peripheral Artery Disease Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Ixaka Ltd, Hemostemix Inc., Caladrius Biosciences, Humacyte

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Peripheral Artery Disease pipeline constitutes 20+ key companies continuously working towards developing 22+ Peripheral Artery Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and … Continue reading →

Pulmonary Fibrosis Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics, Pliant Therapeut

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Pulmonary Fibrosis pipeline constitutes 110+ key companies continuously working towards developing 140+ Pulmonary Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading →

Pin Ads Establishes Itself as Europe’s Leading Pinterest Advertising Agency, Delivering Superior ROAS for Brands Across France and Beyond

The Paris-based Pinterest specialist manages millions of euros in annual ad spend, consistently outperforming Meta and Google benchmarks and is now opening its methodology to the market. In a crowded paid media landscape dominated by Meta and Google, one specialist … Continue reading →

Degenerative Disc Disease Clinical Trial Analysis 2026: Recent FDA Clearances, Ongoing Clinical Studies, and Emerging Treatment Landscape by DelveInsight | Mesoblast, DiscGenics, Biosplice Therapeutic

Degenerative Disc Disease Pipeline According to DelveInsight’s evaluation, the global Degenerative Disc Disease (DDD) pipeline comprises more than 15 prominent companies actively advancing over 15 therapeutic candidates. The analysis encompasses clinical trials, therapeutic approaches, mechanisms of action, routes of administration, … Continue reading →

Juvenile Idiopathic Arthritis Market Set for Robust Expansion Through 2036 Driven by Innovative Biologics and Precision Therapies | DelveInsight

Juvenile Idiopathic Arthritis Market The Juvenile Idiopathic Arthritis market is entering a transformative phase, driven by rapid advancements in targeted therapeutics, increasing disease awareness, and improved diagnostic capabilities. Leading pharmaceutical companies such as Bristol-Myers Squibb, UCB Biopharma, Novartis, AbbVie, Sanofi, … Continue reading →